Cargando…
Molecular Effects of L-dopa Therapy in Parkinson’s Disease
Parkinson’s disease (PD) is one of the most common neurological diseases in elderly people. The mean age of onset is 55 years of age, and the risk for developing PD increases 5-fold by the age of 70. In PD, there is impairment in both motor and nonmotor (NMS) functions. The strategy of PD motor dysf...
Autores principales: | Dorszewska, Jolanta, Prendecki, Michal, Lianeri, Margarita, Kozubski, Wojciech |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958954/ https://www.ncbi.nlm.nih.gov/pubmed/24653659 http://dx.doi.org/10.2174/1389202914666131210213042 |
Ejemplares similares
-
Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and L-Dopa Treatment
por: Rozycka, Agata, et al.
Publicado: (2013) -
Molecular factors in migraine
por: Kowalska, Marta, et al.
Publicado: (2016) -
Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and Biogenic Amines in Parkinson’s Disease
por: Dorszewska, Jolanta, et al.
Publicado: (2013) -
Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
por: Oczkowska, Anna, et al.
Publicado: (2013) -
Genetic Variants in Diseases of the Extrapyramidal System
por: Oczkowska, Anna, et al.
Publicado: (2014)